Los puntos clave no están disponibles para este artículo en este momento.
PR is a promising personalised, multidisciplinary adjunct for severe asthma. Larger phenotype-stratified trials, harmonised outcome sets and implementation research are needed to define candidate selection, optimal dose and cost-effectiveness; embedding PR within severe asthma centres may optimise outcomes and reduce healthcare use.
Guarnieri et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: